Floatz logo

PANITUMUMAB

Malnutrition

University of Pennsylvaniamonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Malnutrition cohort.

Asset / SponsorPhaseRating
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Intralipid
Johane Allard
Phase 4BB
Thalidomide
Chinese University of Hong Kong
Phase 4BB
ClinOleic
Johane Allard
Phase 4BB
Cyclophosphamide
UNICANCER
Phase 2B

View all 14 →

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →